KRT18P61

Across TCGA pan-cancer cohorts, KRT18P61 RNA differs between tumor and matched normal tissue in 9 of 18 cancer types tested, making tumor–normal expression one of KRT18P61’s most consistent transcriptional readouts.

The strongest signal is observed in stomach adenocarcinoma (STAD), where KRT18P61 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types KRT18P61 is over-expressed in tumor.

STAD, HNSC, and COAD are the cancer types where KRT18P61 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in KRT18P61 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
STAD	All	All	+0.252	<.001	10	view →
HNSC	Female	IV	+0.055	.005	7	view →
COAD	All	III,IV	+0.100	.009	4	view →
BLCA	Female	All	+0.045	.006	4	view →
ESCA	All	II,III,IV	+0.459	.018	2	view →
CHOL	Male	All	+0.078	.003	2	view →
LUAD	All	All	+0.061	.024	2	view →
LUSC	Female	III,IV	+0.075	.004	1	view →
KIRC	All	All	+0.012	.049	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 9 strongest of 9 lineages.

KRT18P61–STAD

Open the STAD breakdown →